[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Schrage YM, Machado I, Meijer D, Briaire-de Bruijn I, van den Akker BE, Taminiau AH, Kalinski T, Llombart-Bosch A, Bovée JV: COX-2 expression in chondrosarcoma: a role for celecoxib treatment? Eur J Cancer; 2010 Feb;46(3):616-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A subset of chondrosarcomas arises secondarily in the benign tumour syndromes enchondromatosis (EC) and multiple osteochondromas (MO), and prevention of tumour development would greatly improve prognosis.
  • COX-2 expression was studied in central- and peripheral cartilaginous tumours.
  • Also the role of high-dose prophylactic celecoxib in preventing the development of benign and malignant cartilage tumours in EC and MO patients deserves further investigation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / enzymology. Chondrosarcoma / enzymology. Cyclooxygenase 2 / metabolism. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Celecoxib. Cell Survival / drug effects. Cyclooxygenase 2 Inhibitors / blood. Cyclooxygenase 2 Inhibitors / therapeutic use. Disease Models, Animal. Drug Evaluation, Preclinical / methods. Humans. Male. Mice. Mice, Nude. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20004565.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


2. Kim MW, Lim ST, Sohn MH: Unusual findings of benign enchondroma in the ulna on 3-phase bone scintigraphy. Clin Nucl Med; 2003 Sep;28(9):778-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual findings of benign enchondroma in the ulna on 3-phase bone scintigraphy.
  • Enchondroma is a common benign cartilaginous tumor arising from the medullary cavity, most commonly in the phalanges and metacarpals of the hand.
  • Typically, benign enchondroma shows normal or only slightly increased uptake of a bone-seeking agent on delayed bone scintigraphy.
  • The authors present the 3-phase bone scintigraphic findings of a benign enchondroma associated with pain, which showed focal hyperperfusion, hyperemia, and intense bone uptake in the distal right ulna.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Chondroma / radionuclide imaging. Technetium Tc 99m Medronate. Ulna

  • Genetic Alliance. consumer health - Enchondroma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12973008.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


Advertisement
3. Singh H, Meyer SA, Jenkins AL 3rd: Treatment of primary vertebral tumors. Mt Sinai J Med; 2009 Oct;76(5):499-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These lesions encompass a wide variety of tumor types classified by their cell of origin: bony tumors, cartilaginous tumors, vascular tumors, plasma cell dyscrasias, and tumors that arise from embryonic rests.
  • Further classification of these tumors into malignant or benign subtypes is based on their clinical progression, histopathological evidence of invasiveness, and response to therapy.
  • We provide a brief overview and description of primary tumors as well as treatment paradigms for the individual tumor types.
  • Mt Sinai J Med 76:499-504, 2009. (c) 2009 Mount Sinai School of Medicine.
  • [MeSH-major] Spinal Neoplasms / surgery
  • [MeSH-minor] Humans. Neoplasms / surgery. Paraproteinemias. Vascular Neoplasms / pathology. Vascular Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787656.001).
  • [ISSN] 1931-7581
  • [Journal-full-title] The Mount Sinai journal of medicine, New York
  • [ISO-abbreviation] Mt. Sinai J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down






Advertisement